Based on previous studies suggesting that ROS is involved in drug sensitivity, and our team’s previous research confirming the effect of DUOX2 on 5FU sensitivity, we speculate that the effect of HADHB on CRC’s 5FU sensitivity is achieved by targeting DUOX2 and regulating ROS generation. Here, DUOX2 is linked to colorectal carcinoma.